Vagus nerve stimulation lead removal or replacement: surgical technique, institutional experience, and literature overview

Marlien W. Aalbers 1 · Kim Rijkers 2 · Sylvia Klinkenberg 3 · Marian Majoie 3,5 · Erwin M. J. Cornips 4

Received: 8 June 2015 / Accepted: 7 August 2015 / Published online: 3 September 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract

Background With the growing use of vagus nerve stimulation (VNS) as a treatment for refractory epilepsy, there is a growing demand for complete removal or replacement of the VNS system. We evaluate the safety and efficacy of complete removal or replacement of the VNS system and provide an extensive description of our surgical technique.

Methods We retrospectively reviewed our patient registry for all VNS surgeries performed between January 2007 (the year of our first complete removal) and May 2014. In order to assess patient satisfaction, a written questionnaire was sent to patients or their caregivers. Additionally, we reviewed all literature on this topic.

Results The VNS system was completely removed in 22 patients and completely replaced in 13 patients. There were no incomplete removals. Revision surgery was complicated by a small laceration of the jugular vein in two patients and by vocal cord paralysis in one patient. Seizure frequency was unaltered or improved after revision surgery. Electrode-related side effects all improved after revision surgery. Twenty-one studies reported a total of 131 patients in whom the VNS system was completely removed. In 95 patients, the system was subsequently replaced. The most frequently reported side effect was vocal cord paresis, which occurred in four patients.

Conclusions Complete removal or replacement of the VNS system including lead and coils is feasible and safe. Although initial results seem promising, further research and longer follow-up are needed to assess whether lead replacement may affect VNS effectiveness.

Keywords Vagus nerve stimulation · Lead · Revision · Epilepsy · Neuromodulation

Abbreviations

VNS Vagus nerve stimulation

Introduction

Vagus nerve stimulation (VNS) is a neuromodulatory treatment that consists of chronic intermittent electrical stimulation of the left vagus nerve, delivered by a programmable pulse generator. This pulse generator is implanted subcutaneously in the chest wall and connected to a bipolar lead with three helical coils (two stimulation electrodes and an anchoring tether) wrapped around the cervical part of the vagus nerve. VNS is used as an adjunctive treatment for patients with refractory epilepsy who are not eligible for resective surgery or in whom resective surgery has failed. The treatment is generally well tolerated and severe side effects are rare [4, 13, 15, 26].
Additionally, VNS is approved for refractory depression, while other indications are being investigated including advanced heart failure [3, 20, 21].

Well over 85,000 epilepsy patients have been implanted with a VNS device [7]. With a growing number of implants, a growing need for removal or replacement of the VNS system has emerged. Whereas the generator is removed or replaced routinely, the leads are considered more challenging because of postoperative scarring close to the larynx, internal jugular vein, carotid artery, and electrode-nerve complex. In case of VNS removal it has been advocated to cut the lead a few centimeters proximal to the coils and leave the rest in situ in order not to damage the nerve. However, complete removal may sometimes be necessary, for instance in case of late onset infection or hardware failure e.g. degradation of the silicone coating (Fig. 1). Furthermore, complete removal enables unrestricted use of (high-field) MR imaging techniques that may be needed in patients that are re-evaluated for epilepsy surgery [8]. Finally, some patients in whom VNS is ineffective strongly desire complete explantation of the device. The question therefore arises whether complete removal of VNS lead and coils is feasible, safe, and whether subsequent replacement will affect treatment response. In this paper we report our experience and review the current literature on VNS revision and removal. We demonstrate that complete removal or replacement of the VNS system including lead and coils is feasible and safe, and provide a detailed description of our surgical technique.

Materials and methods

Case selection

The Medical Ethical Committee of Maastricht University Medical Center approved this study. We obtained informed consent to access medical records for research purposes and retrospectively reviewed our patient registry for all VNS surgeries performed at Maastricht University Medical Center, a tertiary referral hospital, between January 2007 (the year of our first complete removal) and May 2014. We retrieved the following data from inpatient and outpatient records: patient sex, age at revision, interval between implantation and revision, presenting symptoms, device diagnostics, indications for removal or replacement, intraoperative findings and hardware failure, complications, and adverse events.

Patient satisfaction

A written questionnaire was sent to all patients or caregivers, asking them whether seizure frequency and severity were “worse”, “unchanged”, or “better” compared with preoperatively and whether they were satisfied with the result of the operation. Patients were also asked whether surgery affected preoperative side effects that occurred with their previous VNS implant, and whether new adverse events or side effects occurred after surgery.

Surgical technique (supplemental video)

All procedures but one were performed by the same neurosurgeon (EC). The operation was performed after administration of intravenous antibiotics and under strict aseptic conditions according to our protocol for surgical implants. The generator was gently moved out of its pocket to disconnect the lead. The horizontal neck incision was reopened, exposing the lead. Both fixation booklets were removed and the lead was carefully followed through the scar tissue medial to the sternocleidomastoid muscle towards the neurovascular bundle containing the carotid, internal jugular vein, and vagus nerve. As in primary implantations, it is imperative to convert an aesthetic horizontal incision into a sufficiently large vertical exposure by mobilizing the platysma on both sides from underlying tissues and keeping it away with a Gelpi retractor positioned parallel to the medial sternocleidomastoid muscle border. The omohyoid muscle is mobilized using sharp dissection and retracted in cranial (or less frequently caudal) direction using the Gelpi retractor. With gentle longitudinal dissection (parallelling the neurovascular structures) using a small

Fig. 1 Intraoperative image: once the generator is moved out of its pocket, degradation of the silicone coating of the lead is clearly visible. Note the exact point where the lead has left the silicone coating (arrowhead) and the trajectory it has subsequently followed (arrow)
scissor with blunt, curved tips the lead is followed to the helices that may easily be palpated before being exposed. This also helps to locate the carotid that may remain attached with its medial border to the laryngeal structures. Likewise, the internal jugular vein may remain attached with its lateral border to the inner surface of the sternocleidomastoid muscle, while the nerve is exposed in between both vessels. The Gelpi is now carefully repositioned paralleling the internal jugular vein, and the operating microscope is installed (supplemental video). The helices are exposed and removed in a cranio-caudal direction. In case of lead removal, the nerve does not need to be detached from adhesions underneath, whereas in case of lead replacement, the nerve needs to be detached very carefully using scissors while it is gently lifted with a vessel loop. Excessive (cranio-caudal) traction on the nerve should be avoided at all times. We have tried microscissors to cut the coils turn by turn, however, we soon discovered that regular scissors with straight and blunt, curved tips do a much better job. Importantly, we have always observed a cleavage plane in between the nerve on the one end and the helices surrounded by multiple layers of scar tissue on the other end. This cleavage plane can be found with surprising ease when the most cranial helix of the most cranial coil is gently lifted and cut with a small scissor under microscopic view. Subsequently, the three coils are removed in a piecemeal fashion, exposing the vagus nerve, which usually looks surprisingly normal thereafter (Fig. 2), except for those rare cases where we observed a kink in the nerve caused by a suboptimal position of the helices and/or strain relief loops. In such patients, short segment atrophy of the nerve due to chronic constriction may be observed (Fig. 3). We never leave a coil behind, and prefer to position the coils of the new lead in the exact same position so as to avoid exposure and devascularization of an unnecessarily long nerve segment. Especially in case of reimplantation, the surgical field is repeatedly irrigated with saline solution containing gentamicin. Once all hardware has been completely removed, reimplanting an entirely new VNS system is as straightforward as the initial procedure, and the wound is closed in a regular fashion.

**Literature review**

We performed a literature search in PubMed, Google Scholar, and Embase using the keywords “vagus nerve stimulation” or “vagal nerve stimulation”, or “VNS”, combined with “removal”, “replacement”, or “revision”. Only original studies written in English, describing removal or replacement of the VNS system including the leads, were included. Whenever it was unclear whether the lead was completely removed, the authors of the original paper were contacted to provide extra information.

**Results**

**Institutional experience**

Between January 2007 and July 2014, 35 patients underwent VNS removal or revision surgery, including 25 adults (mean...
age at surgery 34 years, range, 18–62 years) and ten children (mean age at surgery 16 years, range 11 to 17 years). All revisions (removal with or without replacement) were first revisions and the mean interval between initial implantation and revision was 7 years (range, 1–17 years).

VNS removal

In 19 patients, the VNS system was completely removed. In three additional patients, generator and proximal part of the lead had been removed in another hospital, leaving the distal part of the lead and helices wrapped around the nerve to be removed at our center. All attempted removals were complete, and there were no incomplete removals during the study period in our institution. The interval between lead implantation and removal was on average 7 years (range, 1–14 years). All patients requested removal because VNS was ineffective. Additionally, five patients required high-field MR imaging, two patients experienced paresthesias over a damaged lead, and one patient experienced discomfort because of a subcutaneously mobile generator. In one patient, an 11-year-old boy, full VNS replacement was planned but abandoned because the nerve appeared to be severely damaged and atrophied due to chronic constriction as a consequence of a suboptimal position of the helices and/or strain relief loops. In two patients, a small laceration of the internal jugular vein occurred, which was easily repaired with a polypropylene 6/0 suture.

VNS replacement

In 13 patients, the VNS system was completely removed and replaced on average 8 years (range, 3–17 years) after initial implantation. Nine patients presented with an increasing seizure frequency and/or seizure severity. In two patients, the generator was routinely replaced as the battery was near end of life, however, as we observed a breach in the silicone insulation of the lead (Fig. 1), we decided to replace the entire system. One patient presented with new unexplained side effects (cough and dyspnea) suggesting a dysfunctional lead. Although nothing abnormal was observed intraoperatively, the complaints disappeared after lead replacement. One patient presented with an obvious lead fracture. One patient complained of hoarseness and dysphonia immediately after surgery and was diagnosed with left vocal cord paralysis. At 3-year follow-up, the patient merely experienced stimulation-induced dysphonia, while during the stimulation-free interval, his voice was normal.

Patient satisfaction

At the time of follow-up, two patients were deceased. Sixteen of the remaining 33 patients (48 %) completed and returned the questionnaire, including 11 removals and five replacements. Regarding seizure frequency and severity, three of five patients (60 %) with a replacement reported less frequent and less severe seizures, whereas the other two (40 %) reported no obvious change. Among 11 patients in whom the VNS system was completely removed, two (18 %) reported less frequent seizures and nine (82 %) reported no obvious change, while seizure severity was unaffected in all. Those suffering from electrode-related side effects prior to removal (n=3) reported no more side effects after removal.

Literature review

We identified seven studies [1, 9, 11, 17–19, 30] and five case reports [12, 23, 27–29] focusing on lead removal or replacement. Additionally, nine studies described lead removal or
replacement as part of a broader report on VNS treatment [2, 6, 10, 14, 16, 22, 24, 25, 31]. The included studies are summarized in Table 1. In 131 patients (including 52 children) the lead was completely removed and in 95 of them the lead was replaced. The interval between implantation and removal or replacement ranged between 1 month and 11 years. The main reasons for removal were lack of response and the occurrence of adverse effects, such as increased seizure frequency, unpleasant sensation, or impaired swallowing. Main reasons for replacement were device malfunction and infection. Complete removal or replacement were complicated by vocal cord paresis (n=4), which resolved in three patients [19, 22, 29], but was permanent in one patient [19].

Discussion

VNS is an adjunctive therapy for refractory epilepsy. The first-generation VNS leads (301, 302) have proven to degrade over time, which results in tears in the silicone coating (Fig. 1) that may lead to electrical failure (high impedance) or stimulation related side effects, or even in complete fracture as seen on X-ray examination. Patients that benefit from VNS carrying a first-generation lead are at risk for lead fracture and may require lead revision at some point in their lives. Moreover, with increasing use of VNS for different indications, the demand for removal or replacement will likely increase. With this paper we demonstrate that a complete revision of any VNS device including the leads is feasible, safe, and effective.

In our experience, revision surgery takes about 30 (removal) to 60 (replacement) minutes longer than an initial implantation (which typically takes approximately 45 min), as careful dissection of fibrous scar tissue surrounding the neurovascular bundle under microscopic magnification is needed. Our first few revisions took significantly longer, however, operative time decreases with increasing lead revision experience [1, 9]. A long interval between implantation and revision does not impede complete removal [9, 12], as we have successfully removed leads that had been implanted more than ten years ago. Of note, we have always observed a cleavage plane in between the nerve on the one end and the helices surrounded by multiple layers of scar tissue on the other end. Similarly, a patient’s age does not affect the feasibility of lead revision [19].

The most common adverse event associated with lead revision surgery is vocal cord paresis, which has been reported in five cases including one of our patients (4/131 (3.0 %) in the literature as compared to 1/35 (2.8 %) in our series) [19, 22, 29]. The incidence therefore seems to be slightly higher than after initial implantation, where vocal cord paresis has been reported in approximately 1 % of patients [5]. Vocal cord paresis results from injury to the fibers of the recurrent laryngeal nerve as a result of direct surgical trauma, disruption of the delicate vascularization, and/or secondary inflammation in the nerve’s surroundings, in which case paresis may appear several weeks after revision [22, 29]. In most patients, symptoms subsided completely, even though vocal cord paresis remained in two of them.

Both in our series and in the literature, lead replacement is usually performed because of infection or device malfunction, the former being reported in 3–6 % of patients after initial implantation [5]. Lead salvage by prolonged antibiotic therapy with or without removing the generator may be attempted [31], but persistent infection will necessitate removing all hardware. Lead malfunction usually results from tears in the silicone coating (Fig. 1) or even a complete fracture that occurs either spontaneously or after a trauma. In our series, we observed eight lead failures. In the near future, we expect to see more patients with a first-generation lead (301, 302) requiring lead replacement, however, it is hoped the second-generation leads (303, 304) will prove to be more fatigue-resistant with fewer patients requiring revisions, even long term.

Finally, with regard to the efficacy of a replaced VNS system, Dlouhy et al. reported that the replaced VNS system was as effective as the initial one in 15 out of 16 cases they had operated [9]. Waseem et al. reported that nine out of ten patients reported an equal or improved clinical response compared with their initial VNS system, and none of them reported a worse quality of life [30]. The number of anti-epileptic drugs was unaltered in the vast majority of patients [30]. The answers to our questionnaire seem to confirm these findings. However, they are self-reported and therefore subject to a placebo effect. In order to prove that VNS revision including lead replacement does not negatively influence VNS effectiveness, more research including meticulous analysis from long-term neurological follow-up data is needed.

Conclusions

Our institutional series and overview of the literature confirms that complete removal of all VNS hardware (including the lead and three helical coils) is technically feasible and safe. Although initial results seem promising, further research and longer follow-up are needed to assess whether lead replacement may affect VNS effectiveness. The fact that VNS can be
| Study          | No. of patients | Children in months (range) | Mean interval in months (range) | Old lead removed | Old lead not removed | New lead inserted | Reason (number of patients) | Presenting symptom (number of patients) | Hardware failure (number of patients) | Complications |
|---------------|----------------|---------------------------|--------------------------------|-----------------|---------------------|-------------------|------------------------|--------------------------------------|----------------------------------------|---------------|
| Agarwal 2011  | 23             | 23                        | 30±17                          | 18              | 5                   | 23                | Device malfunction (20)                          | Increased impedance (20)                  | Lead fracture (7) | 0             |
| Air 2009      | 8              | 8                         | n.m.                           | 7               | 1                   | 5                 | Device malfunction (8)                          | Infected wound (8)                        | None          | 0             |
| Ching 2013    | 6              | 0                         | n.m.                           | 6               | 0                   | 0                 | No response (3)                                  | Imaging required (1)                      | Lead fracture (2) | 0             |
| Dlouchy 2012  | 25             | 1                         | 60 (22–133)                    | 25              | 0                   | 25                | Device malfunction (20)                          | Increased seizure frequency (18)         | Lead fracture (3) | 1, taut cable |
| Elliot 2011   | 26             | n.m.                      | n.m.                           | 7               | 19                  | n.m.              | Device malfunction (4)                          | Infection (7)                              | None          | 0             |
| Espinosa 1999 | 10             | 1                         | 44 (13–88)                     | 7               | 3                   | 4                 | No response (5)                                  | Patient choice (1)                        | Lead fracture (4) | 0             |
| Giulioni 2012 | 1              | 0                         | 120                            | 1               | 0                   | 1                 | Device malfunction (4)                          | Device malfunction (1)                    | None          | 0             |
| Khurana 2007  | 2              | 2                         | n.m.                           | 2               | 0                   | 2                 | Device malfunction (1)                          | Patient choice (1)                        | None          | 0             |
| Landy 1993    | 2              | 0                         | 0.5–17                         | 2               | 0                   | 1                 | Device malfunction (1)                          | Adverse event (1)                         | None          | 0             |
| Mac Donald 2004 | 7             | n.m.                      | 12 (1–17)                      | 7               | 0                   | 4                 | No response (2)                                  | Adverse event (1)                         | Lead fracture (1) | 0             |
| Ng 2010       | 8              | 7                         | 38 (6–108)                     | 7               | 1                   | 5                 | Device malfunction (5)                          | Device malfunction (2)                    | Increased seizure frequency (2)         | Lead fracture (1) | 0             |
| Ortler 2010   | 9              | 3                         | 39(13–68)                      | 9               | 0                   | 0                 | No response (9)                                  | Increase impedance (2)                    | Increased impedance (5)                  | Vocal cord paresis (1 permanent, 1 temporary) |
| Rychlicki 2006 | 3              | 2                         | >36                            | 2               | 1                   | 2                 | Device malfunction (2)                          | No response (1)                           | Increased impedance (2)                  | Lead fracture (2) | Temporary vocal cord paralysis (1) |
| Spitz 2010    | 1              | 0                         | 2.5                            | 1               | 0                   | 1                 | Device malfunction (8)                          | Adverse event (1)                         | Pain, dyspnea, phrenic nerve paralysis   | Discontinuity insulation | 0             |
| Spuck 2010    | 9              | nm                        | n.m.                           | 7               | 2                   | 7                 | Device malfunction (8)                          | Adverse event (1)                         | Contraction sternocleidomastoid muscle   | Lead fracture (8) | 0             |
| Tangnelli 2002 | 3              | n.m.                      | n.m.                           | 3               | 0                   | 0                 | Device malfunction (2)                          | Adverse event (2)                         | Pain (1)                                 | Lead dislocation (1) | 0             |
| Tran 2011     | 1              | 0                         | 12                             | 1               | 0                   | 1                 | Device malfunction (1)                          | Device malfunction (1)                    | Increased seizure frequency (1)          | Traumatic lead fracture (1)              | 0             |
| Trout 2013    | 1              | 1                         | 8                              | 1               | 0                   | 1                 | Device malfunction (1)                          | Device malfunction (1)                    | Dysphonia (1)                            | New seizure type                        | Lead fracture (1) | 0             |
| Vassilyadi 2003 | 1             | 1                         | 1                              | 1               | 0                   | 0                 | Device malfunction (1)                          | Adverse event (1)                         | Abnormal wound (1)                       | -                          | Temporary vocal cord paralysis (1)      |
considered fully reversible makes it an even more attractive treatment option.

**Conflict of interest** Dr. Cornips has a consulting agreement with Cyberonics, which involves basic medical consultation, scientific presentations, and occasional surgeries abroad. Dr. Rijkers has a consulting agreement with Cyberonics, which involves basic medical consultation and scientific presentations. The presented research was in no way funded, supported, or reviewed by Cyberonics.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Agarwal G, Wilfong AA, Edmonds JL Jr (2010) Surgical revision of vagus nerve stimulation electrodes in children. Otalaryngol Head Neck Surg 144:123–124

2. Air EL, Ghomri YM, Tyagi R, Grande AW, Crone K, Mangano FT (2009) Management of vagal nerve stimulator infections: do they need to be removed? J Neurosurg Pediatr 3:73–78

3. Beekwilder JP, Beems T (2010) Overview of the clinical applications of vagus nerve stimulation. J Clin Neurophysiol 27:130–138

4. Ben-Menachem E (2001) Vagus nerve stimulation, side effects, and long-term safety. J Clin Neurophysiol 18:415–418

5. Ben-Menachem E, Revesz D, Simon BJ, Silberstein S (2015) Surgically implanted and non-invasive vagus nerve stimulation: a review of efficacy, safety and tolerability. Eur J Neurol. doi:10.1111/ene.12629

6. Ching J, Khan S, White P, Reed J, Rammarine D, Sieradzan K, Sandeman D (2013) Long-term effectiveness and tolerability of vagal nerve stimulation in adults with intractable epilepsy: a retrospective analysis of 100 patients. Br J Neurosurg 27:228–234

7. Cyberonics Inc (2014) Annual Report. http://ir.cyberonics.com/annuals.cfm accessed 06-07-2015

8. de Jonge JC, Melis GI, Gebbink TA, de Kort GA, Leijten FS (2014) Safety of a dedicated brain MRI protocol in patients with a vagus nerve stimulator. Epilepsia 55:e112–e115

9. Dlouhy BJ, Viljoen SV, Kung DK, Vogel TW, Granner MA, Howard MA 3rd, Kawasaki H (2012) Vagus nerve stimulation after lead revision. Neurosurg Focus 32:E11

10. Elliott RE, Morsi A, Kalhorn SP, Marcus J, Sellin J, Kang M, Silverberg A, Rivera E, Geller E, Carlson C, Devinsky O, Doyle WK (2011) Vagus nerve stimulation in 436 consecutive patients with treatment-resistant epilepsy: a long-term outcome analysis. Neurosurg Focus 32:E1

11. Espinosa J, Aiello MT, Naritoku DK (1999) Revision and removal of stimulating electrodes following long-term therapy with the vagus nerve stimulator. Surg Neurol 51:659–664

12. Giuliani M, Marinoni M, Naldi I, Bissi F, Pozzati E, Tinuper P (2012) Successful removal and reimplant of vagal nerve stimulator device after 10 years. Ann Indian Acad Neurol 15:128–129

13. Handforth A, DeGiorgio CM, Schachter SC, Uthman BM, Naritoku DK, Tecoma ES, Henry TR, Collins SD, Vaughn BV, Gilmartin RC, Labar DR, Morris GL 3rd, Salinsky MC, Osorio I,
Ristanovic RK, Labiner DM, Jones JC, Murphy JV, Ney GC, Whelless JW (1998) Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology 51:48–55

14. Khurana DS, Reumann M, Hobdell EF, Neff S, Valencia I, Legido A, Kothare SV (2007) Vagus nerve stimulation in children with refractory epilepsy: unusual complications and relationship to sleep-disordered breathing. Childs Nerv Syst 23:1309–1312

15. Klinkenberg S, Aalbers MW, Vles JS, Cornips EM, Rijkers K, Leenen L, Kessels FG, Aldenkamp AP, Majoie M (2012) Vagus nerve stimulation in children with intractable epilepsy: a randomized controlled trial. Dev Med Child Neurol 54:855–861

16. Landy HJ, Ramsay RE, Slater J, Casiano RR, Morgan R (1993) Vagus nerve stimulation for complex partial seizures: surgical technique, safety, and efficacy. J Neurosurg 78:26–31

17. MacDonald J, Couldwell WT (2004) Revision of vagal nerve stimulator electrodes: technical approach. Acta Neurochir (Wien) 146:567–570, discussion 570

18. Ng WH, Donner E, Go C, Abou-Hamden A, Rutka JT (2010) Revision of vagal nerve stimulation (VNS) electrodes: review and report on use of ultra-sharp monopolar tip. Childs Nerv Syst 26:1081–1084

19. Ortler M, Unterhofer C, Dobesberger J, Haberlandt E, Trinka E (2010) Complete removal of vagus nerve stimulator generator and electrodes. J Neurosurg Pediatr 5:191–194

20. Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Nierenberg AA, Husain MM, Ginsberg D, Cooke RG (2005) Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 58:347–354

21. Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, Lavori P, Howland R, Kling MA, Rittberg B, Carpenter L, Ninan P, Moreno F, Schwartz T, Conway C, Burke M, Barry JJ (2005) Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 58:355–363

22. Rychlicki F, Zamponi N, Cesaroni E, Corpaci L, Trignani R, Ducati A, Scerrati M (2006) Complications of vagal nerve stimulation for epilepsy in children. Neurosurg Rev 29:103–107

23. Spitz MC, Winston KR, Maa EH, Ojemann SG (2010) Insulation discontinuity in a vagus nerve stimulator lead: a treatable cause of intolerable stimulation-related symptoms. J Neurosurg 112:829–831

24. Spuck S, Tronnier V, Orosz I, Schonweiler R, Sepehmia A, Nowak G, Sperner J (2010) Operative and technical complications of vagus nerve stimulator implantation. Neurosurgery 67:489–494

25. Tanganelli P, Ferrero S, Colotto P, Regesta G (2002) Vagus nerve stimulation for treatment of medically intractable seizures. Evaluation of long-term outcome. Clin Neurol Neurosurg 104:9–13

26. The Vagus Nerve Stimulation Study Group (1995) A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. Neurology 45:224–230

27. Tran Y, Shah AK, Mittal S (2011) Lead breakage and vocal cord paralysis following blunt neck trauma in a patient with vagal nerve stimulator. J Neurol Sci 304:132–135

28. Trout AT, Larson DB, Mangano FT, Gonsalves CH (2013) Twiddler syndrome with a twist: a cause of vagal nerve stimulator lead fracture. Pediatr Radiol 43:1647–1651

29. Vassilyadi M, Strawsburg RH (2003) Delayed onset of vocal cord paralysis after explantation of a vagus nerve stimulator in a child. Childs Nerv Syst 19:261–263

30. Waseem H, Raffa SJ, Benbadis SR, Vale FL (2014) Lead revision surgery for vagus nerve stimulation in epilepsy: outcomes and efficacy. Epilepsy Behav 31:110–113

31. Wozniak SE, Thompson EM, Selden NR (2011) Vagal nerve stimulator infection: a lead-salvage protocol. J Neurosurg Pediatr 7:671–675